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Introduction: In clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for
thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of these
drugs in clinical practise.
Methods and results: All patients treated with new oral anticoagulants at Skåne University hospital and Halland
County Hospital Halmstad between 2009 and September 2013 was identified in the Swedish national quality registry
for atrial fibrillation and anticoagulation (AuriculA). Medical records were reviewed to identify thromboembolism and
major bleeding and compared to a warfarin cohort with a time in therapeutic range (TTR) of 76%. There were 826
patients, mean age 70.6, follow up 591 years, with atrial fibrillation treated with NOAC. Dabigatran was the initial drug
in 79% of the cohort. The incidences of ischemic stroke/ TIA and major bleeding were 1.9 (95% CI; 1.0-3.2) and 2.0
(95% CI; 1.1-3.5) per 100 patient-years respectively. The corresponding incidences for warfarin were 1.5 (95% CI; 1.0-2.2)
and 2.5 (95% CI; 1.8-3.3), with no statistical significance between the groups. Two subdural hematomas occurred 0.4
(95% CI; 0.06-1.1) per 100 patient-years. Mean age of patients with complications was 77.9 (±5.9) and 69.3 (±11.3) for
those without (p < 0.001). The discontinuation rate was 6.5% and 1.7% was due to dyspepsia for dabigatran, lower than
the RE-LY trial.
Conclusion: This study, largely based on dabigatran shows that treatment is efficient and safe in everyday clinical
practice and not significantly different compared to a warfarin cohort with tight anticoagulation control.
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Oral anticoagulation with warfarin is an effective treat-
ment for prevention of ischemic stroke and systemic
thromboembolism in atrial fibrillation (AF). However,
the need of regular INR checks and significant interaction
with diet and drugs are detrimental. These concerns have
dramatically been modified with the introduction of the
novel oral anticoagulants (NOACs) – dabigatran, a fac-
tor IIa (thrombin) inhibitor, and the factor Xa inhibitors
rivaroxaban and apixaban [1-3]. The pharmacokinetics of
these preparations is predictable, which means that fre-
quent samplings similar to those that are necessary during* Correspondence: ashkan.labaf@med.lu.se
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unless otherwise stated.treatment with warfarin are redundant. RE-LY (Random-
ized Evaluation of Long-Term Anticoagulant therapy)
compared two doses of dabigatran etexilate against war-
farin in AF patients with 1 or more stroke risk factors.
The 150 mg b.i.d. was superior for the primary efficacy
endpoint with similar a similar rate of bleeding whereas
the 110 mg b.i.d. dose was noninferior to warfarin for the
primary endpoint and superior to warfarin for major bleed-
ing events. ROCKET AF (Rivaroxaban versus Warfarin in
Non valvular atrial fibrillation) compared rivaroxaban once
daily against warfarin and reported noninferiority for effi-
cacy and safety.
The Danish registry study on dabigatran, showed that
the results for dabigatran appear to persist even in every-
day clinical practice [4]. However, this study used registers
searching diagnoses according to The International Classi-
fication of Diseases (ICD) for extraction of data, includingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of renal excretion, especially dabigatran which is why
The European Society of Cardiology recommends that
renal function should be monitored during treatment
with NOAC [5]. Reduced glomerular filtration rate (GFR)
with NOACs is associated with bleeding events [6].
The main purpose of this study was to evaluate the effi-
cacy and safety of treatment with NOAC in three Swedish
centers and compared with a historical cohort treated with
warfarin. As a secondary objective, we assessed predictors
of adverse events by a case control study.Material and methods
All patients treated with NOAC at Halland County Hos-
pital Halmstad, Skåne University hospital in Lund and
Malmö between 2009 and September 2013 was identified
in the Swedish national quality registry for atrial fibril-
lation and anticoagulation (AuriculA). AuriculA was in-
troduced in 2008 at our centres and now contains over
110,000 patients with more than 200 affiliated centers
managing their daily dosing activity of oral anticoagulants,
mainly warfarin, through the system. The program is
web-based and includes decision support for dosing of
warfarin. This methodology ensures that all patients treated
with NOAC at these centres are included, thus reducing
potential selection bias. All medical records and AuriculA
were reviewed to obtain data on sex, indication for anticoa-
gulation treatment, treatment time, complications and
mortality. This cohort was compared to a historical co-
hort of patients from the same centres with warfarin from
2008, also by means of AuriculA [7]. The primary outcome
were ischemic stroke, transient ischemic attack (TIA),
systemic embolism, acute myocardial infarction (AMI) and
major bleeding. AMI was defined as type 1 MI [8]. The
International Society on thrombosis and Haemostasis def-
inition on major bleeding was used (fatal bleeding, and/or
symptomatic bleeding in a critical area of organ, such as
intracranial or pericardial or intramuscular with compart-
ment syndrome, and/or bleeding causes a fall in haemoglo-
bin level of 20 g/L or more, or leading to transfusion of
two or more units of red cells [9].
A case control study was performed to identify risk fac-
tors including kidney function, CHADS2, CHA2DS2-VASc
and HAS-BLED for ischaemic stroke/TIA and major
bleeding among patients with atrial fibrillation treated
with a NOAC. The case group was defined as those who
suffered of stroke/TIA or major bleeding event. The con-
trol group was defined as patients with NOAC treatment
without an adverse event and was matched by age, sex
and type of medication. For every case, three subjects were
randomly selected as controls. Eleven cases with stroke/
TIA were matched with 33 controls, and 12 cases with
major bleeding were matched with 36 controls.From the medical records, data on plasma creatinine,
CHA2DS2-VASc and HAS-BLED were obtained for the
case control group. Estimated-GFR (eGFR) was calculated
by the Lund-Malmö equation [10]. The protocol was based
on renal monitoring at treatment initiation, after 3, 6 and
12 months of treatment and thereafter annually except in
subjects with reduced renal function who were monitored
biannually.
Statistical analysis
Categorical data were described by percentages and com-
pared using the chi-square test, and Student’s t-test was
used for continuous data. The days at risk were extracted
from AuriculA for each patient and Incidence rates were
calculated using the Person time module in Openepi, ver-
sion 3.01 (www.openepi.com) with 95% confidence inter-
vals. Multivariate logistic regression analysis was used to
identify risk factors associated with thrombosis and major
bleeding in the case control study. The control group
were matched by age and gender and type of medication
(Dabigatran and Rivaroxaban). All tests were performed
two-tailed, and a p-value <0.05 was considered significant.
All other analyses were performed using SPSS Statistics
(Version 21; SPSS Inc., IBM Corporation, NY, USA).
Results
In total 901 patients was identified in AuriculA. When
medical records were reviewed it appeared that 11 had
not taken the medication and were excluded. Another four
were excluded due to unclear indication. Of the remaining
886 patients, 826 had the indication atrial fibrillation, and
58 had venous thromboembolism. Nine patients had both
AF and venous thromboembolism (VTE) and are included
in the AF group. Baseline characteristics and outcomes for
all NOACS with AF are presented in Additional file 1:
Table S1. Total time in treatment was 590 years of which
84 (10%) had a history of stroke or TIA. The most used
drug was dabigatran, which was the initial drug in 78.5%
of the patients. The dose was adjusted or altered to an-
other NOAC in 5.8% of the patients. Patient that received
dabigatran 110 mg were older than the 150 mg group,
77.2 (±8.5) vs 66.0 (9.2), p < 0.001 and the warfarin group,
75.0 (±9.6), p =0.002. The small group and few adverse
events in the rivaroxaban groups were too small for ana-
lysis and conclusions. Apixaban was approved and intro-
duced later and only a few patients were treated during
this period.
The incidence of major bleeding and stroke/TIA events
for the NOACs were not significantly different from the
warfarin cohort. Twelve cases of major bleeding occurred.
Seven gastrointestinal, 2 subdural haematomas, 1 muscular
haematoma, 1 scalp wound and 1 critical bleeding in an
eye. Another 2 occurred during surgery and invasive
procedure and was excluded since it was iatrogenic and
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as recommended, before the intervention or not. The inci-
dence of gastrointestinal bleeding for all the NOACs com-
bined was 1.2 (95% CI; 0.5-2.3) per 100 patient-years.
There were 6 ischemic strokes, 5 TIA and 2 AMI in
the cohort. There was also one occlusion of an arterio-
venous fistula in a patient treated with plasmapheresis.
The latter was excluded because the lack of indication for
NOAC-treatment. Mean age for patients with TE was 79.9
(±6.3) compared to those without TE 70.6 (±10.3), p =0.01.
Corresponding ages for major bleeding was 77.2 (±5.6) and
70.6 (10.3), p =0.02 respectively.
Twelve deaths occurred during the treatment corre-
sponding to an incidence of 2.0 (95% CI; 1.1-3.5) per 100
treatment years. Two were due to ischemic strokes, 3 in
the final stage of malignancy, 3 cases of end-stage heart
failure, 1 pneumonia, 1 gastroenteritis, and 1 due to an
AMI.
Adverse events and discontinuation of the different
drugs are presented in Additional file 1: Table S2. Adverse
events not related to primary outcome was 5.9% and 4.4%
for dabigatran 110 mg and 150 mg respectively. The most
common adverse event was dyspepsia which occurred in
2.7% and 1.2% respectively, and lower than the RE-LY trial
(11.8% and 11.3%). The discontinuation of dabigatran 110
and 150 mg were 7.3% and 6.1% respectively.
The case control group consisted of 22 subjects with
23 complications which is presented in Additional file 1:
Table S3. Diabetes was significantly associated to major
bleeding with the unadjusted odds ratio of 4.1 (95% CI;
1.0-16.8). CHADS2 and HAS-BLED was significantly higher
in the cases with stroke/TIA compared to the controls and
CHA2DS2-VASc had a borderline significant trend. Renal
function was not significantly different between the cases
and controls in neither group.
Discussion
This present study, which includes all patients with
NOAC-treatment in three major centres in Sweden, dem-
onstrates the incidence of thrombotic, major bleeding and
mortality in a clinical setting. We show that stroke/TIA
and major bleeding were not significantly different between
NOAC-treated patients and the warfarin-treated subjects
with a TTR of 75.8%. In the RE-LY and ROCKET AF trials,
mean TTR were 64% and 55%. The total incidence rate of
all NOACs, which primarily consist of dabigatran and to a
lesser extent rivaroxaban, for stroke/TIA and major bleed-
ing, were 1.9 and 2.0 per 100 patient-years respectively. In
the RE-LY trial, the rate of stroke/systemic embolism were
1.53%/year in the group that received 110 mg b.i.d. and
1.11%/year in the group that received 150 mg b.i.d. The
bleeding events were 2.71%/year and 3.11%/year respect-
ively. For comparison, the present study reported a higher
incidence for the group that received dabigatran 110 mgb.i.d., stroke/TIA (3.8%/year) and major bleeding (3.3%/
year). Patient that received dabigatran 110 mg were older
than the 150 mg group, the warfarin group and older than
the dabigatran 110 mg group in the RE-LY trial, (71.4
(±8.6), p < 0.001). The older age and associated comor-
bidities that accompanies might account for the increased
rate of adverse events. In a subgroup analysis of the
RE-LY [11], there was a highly significant interaction
between treatment and age for major bleeding, such
that patient older than 75 had less benefit on major
bleeding than younger patients, irrespective of the renal
function.
Compared with the warfarin group and RE-LY trial, the
dabigatran 150 mg group was not significantly different.
The incidence of stroke 1.0%/year were similar to the
RE-LY (1.11%/year) and the warfarin group (1.5%/year).
The bleeding rate of 1.6%/year was lower than the RE-LY
trial (3.11%/year) but not significant, p = 0.16, and lower
than the warfarin group (2.5%/year), p = 0.46. These data
corresponds well with a subgroup analysis of the RE-LY
[12], which demonstrated that 150 mg dabigatran was not
superior at reducing the risk of stroke at higher TTR
setting, as in our warfarin cohort. Further, the use of con-
tinuous aspirin in 40% of the patients in the RE-LY trial
might partly have led to the higher bleeding rates. Aspirin
was used in only two patients in the present study. Also,
the RE-LY trial did not stratify the different doses during
randomization according to the patient characteristics
which may explain the differences in adverse events
between our patients and RE-LY. This implies for in-
stance that patients older than 75 and creatinine clear-
ance between 30–45 ml/minute in RE-LY were treated
with dabigatran 150 mg b.i.d.. The few intracranial bleed-
ing (two subdural haematomas) that occurred (0.4%/year)
is persistent with the randomized controlled studies con-
cerning NOAC.
The adverse events were lower compared to the RE-LY
trial. Dyspepsia which was the most common adverse
event, occurred in 1.7% of the dabigatran patients com-
pared to over 11% in the RE-LY trial. The observation
and reporting of adverse effects are usually more accur-
ate and careful in randomized controlled trials than in
clinical practise which may explain some of the differ-
ence. Under-reporting of adverse drug reactions in real
life is extensive and estimated to be in excess of 90%
[13]. Nevertheless, the rate of adverse events seems not
to outweigh the data from the RE-LY trial. The discon-
tinuation rate of dabigatran was 6.5% (250 median treat-
ment days) and due to primary outcome including death
but also due to worsening renal failure and ablation treat-
ment compared to the RE-LY trial which was 15% and
16% for each doses at one year of follow up. The patient’s
decision for discontinuing was over 7% in RE-LY which
could have been attributable to the increasing vigilance of
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ation rate in real life is however reassuring.
In the Danish “Real-World” study [4], the crude rates
of stroke and major bleeding for dabigatran 150 mg were
3.5 and 2.2 per 100 patient-years respectively, and corre-
sponding incidences for dabigatran 110 mg were 2.7 and
2.8 per 100 treatment years. The mean CHADS2 score
was 1.2 and mean age 67.4 (dabigatran 150 mg) and 74.7
(dabigatran). A minor proportion of these patients could
have represented AF cardioversions and ablations which
reflect the real world clinical practise. However, an untold
numbers of patients did not presumably satisfy the require-
ments for anticoagulation treatment for the prevention of
stroke/systemic embolism. This would explain the higher
adverse events for dabigatran 110 mg in our cohort, but
not the lower incidence of stroke for dabigatran 150 mg
group, (p = 0.02). Another recent single centre experience
of dabigatran in Asia [14], showed surprisingly low inci-
dence of adverse events, with only 2 major bleeding events
(0.4%) and 1 stroke (0.2%). Recently FDA (The U.S. Food
and Drug Administration) announced the new study in
Medicare comparing dabigatran to warfarin which included
134,000 patients [15]. Dabigatran was associated with a
lower risk of ischemic strokes, intracranial haemorrhage
and death compared to warfarin. The MI risk was similar
and an increased risk of major gastrointestinal bleeding
were found in the patients with dabigatran treatment.
The renal function in the present study was strictly
monitored in all patients according to the guidelines. This
has not been presented in other real-life follow-up studies
including the aforementioned studies. In fact, another
Danish study showed that when recommendations set
by the European Medicine Agency were not fulfilled, the in-
cidence of adverse events were higher than warfarin-treated
patients [16]. At our centres, all physicians that initiate
treatment with any anticoagulant, will automatically notify
the anticoagulation clinic. This course entails that specific
protocols regarding renal function, adverse events, con-
comitant drugs are monitored and altered when needed.
The renal function was not significantly different between
the cases and controls, probably as a result of selecting
patients without renal impairment according to the
guidelines, but also because of an active monitoring with
adjustment of dose or discontinuation of the drug in pa-
tients with progressive renal failure. This also shows that
surveillance of renal function is useful and works well at
our units.
Conclusions
The present study which is largely based on treatment
with dabigatran, shows that these agents are effective in
preventing stroke and systemic embolism in atrial fibril-
lation in a real life clinical setting, and not statistically
different compared to a warfarin cohort with a high TTR(76%). With regular monitoring of renal function and
thereafter adjusted dose, the complication rate is low and
intracranial bleeding is rare. The adverse events and
discontinuation rate was lower for dabigatran than in
the RE-LY trial.
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